Fintel reports that on October 24, 2024, Raymond James initiated coverage of Q32 Bio (LSE:0T6G) with a Strong Buy recommendation.
What is the Fund Sentiment?
There are 90 funds or institutions reporting positions in Q32 Bio. This is an increase of 43 owner(s) or 91.49% in the last quarter. Average portfolio weight of all funds dedicated to 0T6G is 0.13%, an increase of 58.04%. Total shares owned by institutions increased in the last three months by 8.78% to 8,056K shares.
What are Other Shareholders Doing?
Orbimed Advisors holds 2,253K shares representing 18.68% ownership of the company. No change in the last quarter.
Atlas Venture Life Science Advisors holds 2,092K shares representing 17.35% ownership of the company. No change in the last quarter.
Carlyle Group holds 1,103K shares representing 9.14% ownership of the company. No change in the last quarter.
Arch Venture holds 320K shares representing 2.66% ownership of the company. No change in the last quarter.
Temasek Holdings holds 314K shares representing 2.60% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
